Market Currents

• Monday, November 2, 2009

• 09:10 AM Dendreon (DNDN) completes its regulatory submission for closely-watched experimental prostate cancer vaccine Provenge. If approved, Provenge would be the first therapeutic cancer vaccine. Company expects response by mid-2010. Shares +5% premarket. Comment!
• 09:00 AM Premarket gainers: HGSI +33%. EAC +24%. TRA +12%. VRTX +11%. F +9%. AMLN +7%. DNDN +5%. AXL +5%. MOT +5%. CTIC +5%. PGR +5%. PRGO +5%. ALU +4%. MI +4%. JWN +4%. GNW +4%. THC +4%.
  Losers: CTXI -34%. AIB -10%. LDK -9%. NTES -5%. DSCO -4%. Comment!

• Friday, September 18, 2009

• 09:38 AM FDA issues draft guidance for cancer vaccines that indicates it will consider therapies that extend survival, even if they don't delay progression. Dendreon (DNDN) +1.9% early on; this is the first acknowledgment of DNDN's regulatory approach for Provenge. Comment!

• Thursday, July 23, 2009

• 15:39 PM After Medarex (MEDX +89%) fetched a healthy premium from Bristol-Myers Squibb (BMY +3.1%), investors have begun looking at similar companies to see who's next up for bids: Regeneron Pharmaceuticals (REGN +8.8%)? Seattle Genetics (SGEN +5.6%)? Alexion (ALXN +7.6%)? Allos Therapeutics (ALTH +6.9%)? Celldex Therapeutics (CLDX +6.7%)? Dendreon (DNDN +6.6%)? Comment!

• Monday, July 6, 2009

• 09:00 AM Premarket gainers: FRPT +5%. DNDN +5%. GERN +5%.
  Losers: SPPI -16%. LDK -8%. CTIC -8%. SSL -7%. RTP -6%. LCC -6%. GFI -6%. HMY -5%. BHP -5%. GST -5%. SAY -5%. DDSS -5%. GOLD -4%. MT -4%. Comment!

• Sunday, June 28, 2009

• 17:19 PM If you haven't been following Mark Mitchell's account (I, II, III, IV) of the short-sellers' attack on Dendreon (DNDN), it's a fascinating Sunday read. 5 Comments

• Monday, May 11, 2009

• 13:09 PM Dendreon (DNDN) is up 9% today to $21.03, despite last week's secondary offering, which priced at $19.20. One reason: table-pounding comments by bullish analysts. Comment!

• Monday, May 4, 2009

• 09:00 AM Premarket gainers: KFN +17%. COT +13%. CENX +13%. CYOU +12%. LIZ +11%. ACAS +11%. S +9%. FIG +9%. PCX +8%. EGLE +8%. ETFC +8%. MPEL +7%. YGE +6%. RCL +6%. DRYS +6%. ICO +7%. SQNM +5%. CAL +5%.
  Losers: DNDN -3%. NVAX -2%. STD -2%. Comment!

• Thursday, April 30, 2009

• 11:28 AM So what exactly drove Dendreon (DNDN) shares down as low as $7.50 from $24.25 in minutes? Rumors? Mass panic? Fat finger? 4 Comments

• Wednesday, April 29, 2009

• 09:00 AM Premarket gainers: DNDN +135%. DWA +21%. UFS +14%. SLAB +12%. AMX +9%. ING +8%. BCS +8%. AAUK +8%. BZH +8%. SSW +7%. Q +6%. ELN +6%. FIG +6%. CIT +6%. MGM +6%. DAL +5%. HBAN +5%. TSM +5%. UBS +5%. C +5%. GM +4%. FITB +4% CDE +5%. CAL +5%. SNY +4%. ATVI +4%. MPEL +4%. GNA +4%. RF +4%. AMR +4%. ARMH +4%. OEH +4%. UAUA +4%. ODP +4%. TKC +4%. SPIL +4%. LVS +4%. DRYS +4%. 1 Comment
• 08:55 AM Not long ago, boutique firm Brean Murray was a Dendreon (DNDN) bear, with a Sell rating on the stock going into the Apr. 14 preliminary IMPACT trial data. Following that, firm went Neutral, and today it upgrades shares to Buy with an aggressive $35 target. DNDN +135% premarket to $27.71. Comment!

• Tuesday, April 28, 2009

• 14:10 PM Dendreon (DNDN) says Provenge extended median survival of advanced prostate cancer patients by 4.1 months (25.8 vs. 21.7). It also improved 3-year survival by 38% (31.7% vs. 23%). Earlier on CNBC, a guest from Biotech Stock Research said that an added survival number of three months would be great, and anything over four months would be a homerun. Shares are likely to remain halted until after the conference call at 5:30 ET. (earlier) 2 Comments
• 13:57 PM Not clear whether the sudden plunge in Dendreon (DNDN) was due to leaked results of this afternoon's presentation of data on prostate cancer drug, Provenge, or just the jitters. But what a plunge. Shares are now halted. Meeting is slated for 3:20. 9 Comments

• Wednesday, April 22, 2009

• 09:00 AM Premarket gainers: PFCB +17%. SNDK +8%. F +8%. MEDX +7%. GERN +6%. GILD +6%. SLW +5%. ELN +5%. DNDN +4%. STEM +4%. GM +5%. BA +4%. TROW +4%. BRCD +4%.
  Losers: PPDI -19%. FRE -12%. FITB -9%. RF -9%. COF -8%. PUK -9%. MS -8%. JAH -8%. ETFC -8%. HBAN -8%. PXP -7%. TXT -7%. VNO -6%. ILMN -6%. AMD -6%. USB -5%. WFC -5%. TCK -5%. BHP -5%. HBC -5%. AKS -5%. HIG -5%. Comment!

• Monday, April 20, 2009

• 09:00 AM Premarket gainers: JAVA +37%. PPHM +23%. PBG +18%. QTM +10%. LVS +6%. CDE +5%. HMY +5%. PALM +4%. AIB +4%. DNDN +4%. AUY +4%.
  Losers: BBEP -30%. MT -9%. ING -9%. BCS -8%. CSE -8%. DB -8%. BAC -8%. HBC -8%. C -8%. MGM -7%. IAG -7%. RTP -7%. ETFC -7%. COF -6%. ALU -6%. WFC -6%. RF -6%. ACAS -6%. CCL -6%. HBAN -6%. ERIC -5%. ORCL -5%. IFX -5%. TCK -5%. SOL -5%. NVDA -5%. PHG -5%. Comment!

• Tuesday, April 14, 2009

• 09:04 AM Dendreon (DNDN) reopens (it was halted until 9:00) +235% to $24.35, after revealing its much-discussed Provenge prostate cancer treatment met its primary endpoint (prolonged survival) in a Phase III trial. Comment!